title: Should we be using 5-HT3 antagonists as first line antiemetic therapy in cisplatin-based chemotherapy?
authors.forename: J L
authors.initials: JL
authors.lastname: Mansi
authors.forename: T R
authors.initials: TR
authors.lastname: Evans
authors.forename: A
authors.initials: A
authors.lastname: Smith
authors.forename: C
authors.initials: C
authors.lastname: Oakley
authors.forename: R
authors.initials: R
authors.lastname: Wastnage
authors.forename: A
authors.initials: A
authors.lastname: Dalgleish
mesh_terms: D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D017294:Ondansetron / Q000008:administration & dosage; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D012702:Serotonin Antagonists; D017294:Ondansetron; D003907:Dexamethasone; D002945:Cisplatin